



King's Research Portal

DOI:

[10.1111/dom.12929](https://doi.org/10.1111/dom.12929)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Stadler, M., Bollow, E., Fritsch, M., Kerner, W., Schuetz-Fuhrmann, I., Krakow, D., Merger, S., Riedl, M., Jehle, P., & Holl, R. W. (2017). Prevalence of elevated liver enzymes in adults with type 1 diabetes: A multicentre analysis of the German/Austrian DPV database. *Diabetes, obesity & metabolism*, 1171-1178. <https://doi.org/10.1111/dom.12929>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

**Prevalence of elevated liver enzymes in adults with type 1 diabetes mellitus in routine clinical care
A multicentre analysis in 9226 adults with type 1 diabetes mellitus from the Austrian/German Diabetes prospective documentation system**

| | |
|-------------------------------|--|
| Journal: | <i>Diabetes, Obesity and Metabolism</i> |
| Manuscript ID | DOM-16-0842-OP.R1 |
| Manuscript Type: | Original Paper |
| Date Submitted by the Author: | n/a |
| Complete List of Authors: | Stadler, Marietta; Kings College London, Diabetes Research Group Bollow, Esther; Institute for Epidemiology and Medical Biometry, Ulm University, Ulm, Germany Fritsch, Maria; Medical University Vienna, Pediatrics Kerner, Wolfgang; Centre of Diabetes and Metabolic Disorders Schuetz-Fuhrmann, Ingrid; Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhugel, 3rd Medical Department Krakow, Dietmar; Diabeteszentrum Forchheim Merger, Sigrun; Diabetes and Endocrinology Department, Klinikum Coburg Riedl, Michaela; Medizinische Universitat Wien Klinische Abteilung fur Endokrinologie und Stoffwechsel Jehle, Peter; Academic Hospital Paul Gerhardt Stift; Martin-Luther-University Halle-Wittenberg, Department of Internal Medicine Holl, Reinhard; University of Ulm, Institute of Epidemiology and Medical Biometry |
| Key Words: | diabetes complications |
| | |

Prevalence of elevated liver enzymes in adults with type 1 diabetes mellitus in routine clinical care

A multicenter analysis in 9226 adults with type 1 diabetes mellitus from the Austrian/German Diabetes prospective documentation system

Marietta Stadler^{1,2}, Esther Bollow^{3,4}, Maria Fritsch⁵, Wolfgang Kerner⁶, Ingrid Schuetz-Fuhrmann², Dietmar Krakow⁷, Sigrun Merger⁸, Michaela Riedl⁹, Peter Jehle¹⁰, Reinhard W Holl^{3,4} for the DPV Initiative and the German BMBF Competence Network Diabetes mellitus

- 1) Diabetes Research Group, King's College London, London, UK
- 2) Hietzing Hospital Vienna, 3rd Medical Department, Vienna, Austria
- 3) Institute for Epidemiology and Medical Biometry, Ulm University, Ulm, Germany
- 4) German Centre for Diabetes Research (DZD)
- 5) Medical University Vienna, Department of Pediatric and Adolescent Medicine, Vienna, Austria
- 6) Klinik für Diabetes & Stoffwechselkrankheiten, Klinikum Karlsburg der Klinikgruppe Dr. Guth GmbH & Co. KG, Karlsburg, Germany
- 7) Diabeteszentrum Forchheim, Forchheim, Germany
- 8) Diabetes and Endocrinology Department, Klinikum Coburg, Germany
- 9) Medical University Vienna, Internal Medicine III, Vienna, Austria
- 10) Klinik für Innere Medizin I, Ev. Krankenhaus Paul-Gerhardt-Stift, Paul-Gerhardt-Diakonie Krankenhaus und Pflege GmbH, Lutherstadt Wittenberg

Corresponding author

Priv. Doz Dr Marietta Stadler

Diabetes Research Group

King's College London

Denmark Hill Campus

10 Cutcombe Rd

SE5 9RJ

London UK

Marietta.stadler@doctors.org.uk

Marietta.stadler@kcl.ac.uk

Words in main text: 3033

Words in abstract: 245

Keywords: Type 1 diabetes, liver enzymes, cardiovascular

Abstract

Aims. To assess the prevalence of elevated liver enzymes in adults with type 1 diabetes mellitus (T1DM) in routine clinical care and the association with cardiovascular risk profile in the Diabetes-Prospective-Documentation (DPV) network in Germany and Austria.

Methods. This cross sectional observational study from the DPV registry includes data from 45519 adults with T1DM at 478 centers up to 9/2016. Liver enzyme measurements were available in 9226 (29%) patients at 270 centers and were analyzed for increased alanine aminotransferase (ALT; men>50 U/l, women: >35U/l) and/or aspartate aminotransferase (AST; men >50 U/l, women >35U/l) and/or gamma-glutamyltransferase (GGT; men >60U/l, women>40 U/l). A subgroup analysis in patients in whom two or more ALT measurements were available (n=2335, 25%) and whose ALT was increased at least twice (men:>30 U/l, women >19U/l) was performed. Associations with glycemic control, cardiovascular risk factors and late complications were investigated with multiple regression analyses.

Results. Twenty percent (19.8%, n=1824) had increased liver enzyme(s) on one or more occasions. Increased liver enzymes were associated with worse glycemic control and higher BMI (both $p<0.0001$), dyslipidemia (OR:1.75, 95%CI: 1.54-2.0), hypertension (OR:1.48, 95%CI:1.31-1.68), myocardial infarction (OR:1.49; 95%CI:1.17-1.91) and end stage renal disease (OR:1.59; 95%CI:1.17-2.17). ALT was increased twice in 29% and was associated with worse glycemic control ($p<0.0001$), higher BMI ($p<0.0001$), hypertension (OR:1.58, 95%CI:1.26-1.97) and dyslipidemia (OR:1.89, 95%CI:1.51-2.37).

Conclusions. In this clinical audit in adults with T1DM, elevated liver enzymes on routine assessment were associated with a less favorable cardiovascular risk profile and with poorer glycemic control.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abbreviations:
T1DM- type 1 diabetes mellitus
DPV- Diabetes-Prospective-Documentation network in Germany and Austria
ALT- alanine aminotransferase
AST- aspartate aminotransferase
GGT- gamma-glutamyl transferase

For Review Only

Introduction

The clinical management of Type 1 diabetes mellitus (T1DM) focuses on preventing and treating acute as well as chronic complications by optimizing glycemic control and tackling additional risk factors. This includes routine screening for nephropathy, retinopathy and neuropathy to allow early secondary prevention [1]. Annual assessment of liver function is recommended in diabetes clinical practice guidelines [1] because diabetes mellitus doubles the risk for chronic non alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma [2, 3]. Type 2 diabetes and NAFLD share insulin resistance/hyperinsulinemia as underlying pathophysiology, therefore NAFLD is a well documented comorbidity of type 2 diabetes [4-6].

In contrast, the clinical significance of measuring liver enzymes in T1DM as part of the annual screening for complications is unclear: T1DM is an autoimmune condition with absolute insulin deficiency and is not per se usually accompanied by features of metabolic syndrome. However, the prevalence of the metabolic syndrome is increasing in both the general population, and in people with T1DM [7]. The cardiovascular risk profile in people with T1DM demands prescription of drugs that can have hepatotoxic side effects.

The real-life clinical practice of routinely measuring liver enzymes as well as the prevalence of increased liver enzymes in people with T1DM in routine clinical care, have not as yet been documented in larger surveys. Therefore it seemed timely to assess the prevalence of elevated liver enzymes in adults with T1DM in a cross sectional multicenter and multinational clinical audit database. Further we wanted to investigate associations between increased liver enzymes, glycemic control, cardiovascular risk profile and diabetes late complications in people with T1DM.

Subjects and Methods

Data collection.

The German/Austrian Diabetes Patienten Verlaufsdokumentation (DPV) prospective documentation system is a nationwide multicentre survey [8] founded in 1990, comprising up until September 2016 data from 452508 patients.

The individual centers enter their patient data into a standardized electronic patient record. The anonymized data sets are exported biannually to the central database in Ulm, Germany, where the data and diagnoses undergo a plausibility check and queries are returned to participating centers. Once the queries have been resolved the data are aggregated into a cumulative database for clinical research and quality assurance. The DPV database is a resource for clinical quality management and benchmarking as well as for research .

All people with T1DM over the age of 20 years, in whom insulin therapy was clearly documented, were considered for this analysis. People with type 2 diabetes, people with other forms of diabetes (secondary to e.g. cystic fibrosis or hemochromatosis, gestational diabetes) were excluded. Of the 111498 people with T1DM in the DPV registry, there were 45519 adults with T1DM over the age of 20 years. Liver enzymes had to be measured at least once in the previous 12 months (from the date of data extraction). Patients with a history of hepatitis, celiac disease, alpha-1-antitrypsin deficiency, alcoholism and persons consuming ≥ 24 g (males) or ≥ 12 g (females) alcohol per day were excluded from the analysis as per national recommendations for maximum alcohol consumption (<http://www.drinkingandyou.com/site/pdf/Sensibledrinking.pdf>).

1
2
3 History of celiac disease was an exclusion criterion, because celiac disease per se can
4
5 be associated with increased liver transaminases [9]. A detailed flow-chart is provided
6
7 in figure 1.
8

9
10 The analyses of the anonymized routine clinical data within the German/Austrian
11
12 Diabetes Prospective Documentation Initiative (DPV) have been approved by the
13
14 Ethics Committee of the Medical Faculty of the University of Ulm and the local
15
16 institutional review boards.
17

18
19 The data forming the basis of this report are anthropometry (age, sex, body mass
20
21 index, waist circumference, diabetes duration), diabetes therapy modality
22
23 (conventional insulin therapy- i.e. twice daily mix-insulin, intensified insulin therapy
24
25 according to basis-bolus-principle, continuous subcutaneous insulin infusion with
26
27 insulin pumps), general data on medication and self reported alcohol intake.
28

29
30 Migration background was defined as having either a mother and/or a father who was
31
32 not born in Austria or Germany. Laboratory data were derived from each center's
33
34 local routine laboratory measurements and included HbA1c, lipid profile and liver
35
36 enzymes [including Alanine aminotransferase (ALT), aspartate aminotransferase
37
38 (AST) and γ -glutamyl transferase (GGT)]. Local HbA1c values were mathematically
39
40 standardized to the Diabetes Control and Complications Trial (DCCT) reference range
41
42 (20-42mmol/l; 4.05-6.05%) using the multiple-of-the-mean transformation method
43
44 [10, 11].
45
46
47
48

49 Data analyses.

50 Increased liver enzymes

51
52
53
54 Increased liver enzymes were defined as one or more measurement of:
55
56
57
58
59
60

1
2
3 Alanine aminotransferase (ALT) >50 U/l in men/ >35 U/l in women, aspartate
4
5 aminotransferase (AST) >50 U/l in men/ >35 U/l in women and/or γ -glutamyl
6
7 transferase (GGT) >60 U/l in men/>40 U/l, according to the definition of the German
8
9 Liver Foundation ([http://www.deutsche-leberstiftung.de/check-up/GPT-Faltblatt-
10
11
12 0109-NETZ.pdf](http://www.deutsche-leberstiftung.de/check-up/GPT-Faltblatt-0109-NETZ.pdf)).

13
14 An additional analysis was performed with lower cut-off values for ALT (males ≥ 30
15
16 U/L and females (≥ 19 U/L) [12], categorizing those patients into the group of T1DM
17
18 with increased ALT, whose ALT was above this threshold in at least two
19
20 measurements.

21 22 Comorbidities and complications.

23
24 Hypertension was defined by the use of antihypertensive medication or by increased
25
26 systolic (≥ 140 mmHg) and/or diastolic (≥ 90 mmHg) arterial blood pressure
27
28 according to current guidelines [13]. Dyslipidemia was defined as either taking lipid
29
30 modifying drugs or having decreased high-density lipoprotein (HDL) cholesterol
31
32 values (< 35 mg/dl), or by at least one increased value of total cholesterol (> 200 mg/dl),
33
34 low density lipoprotein (LDL) cholesterol (> 130 mg/dl), or triglycerides (> 150 mg/dl)
35
36 values.

37
38 Data on prevalence of late complications including end stage renal disease,
39
40 myocardial infarction, stroke, or major lower limb amputation were available from the
41
42 DPV database. End stage renal disease was defined as either having received a renal
43
44 transplantation, being on hemo- or peritoneal dialysis treatment, or a calculated eGFR
45
46 below 15ml/min/1.73 [14].
47
48
49
50
51

52
53
54 In order to address the issue of potential heterogeneity between centers as to the
55
56 frequency with which they are measuring liver enzymes, we conducted two additional
57
58
59
60

1
2
3 analyses to better understand the data set available: We compared data from centers in
4
5 which liver enzymes were measured in more than 50% of their patients with data from
6
7 centers that conduct less frequent measurements.
8

9
10 A comparison was made between patients in whom liver enzymes were available and
11
12 those patients whose liver enzymes were not measured/ reported. The results are
13
14 provided as supplemental material.
15

16
17
18 Statistical analyses were performed using the software package SAS version 9.4
19
20 (Statistical Analysis Software, SAS Institute; Cary, NC). Sociodemographic and
21
22 clinical characteristics are presented as median and interquartile range (Q1,Q3) or as
23
24 percentage, unless stated otherwise. Two-sided p value of <0.05 was considered to be
25
26 significant. For group comparison, Wilcoxon testing for continuous and X^2 tests for
27
28 categorical data were used. The Holm method was applied to adjust p -values for
29
30 multiple comparisons. Multiple logistic regression models for dichotomous variables
31
32 (prevalence of hypertension, dyslipidemia, macrovascular complications and end
33
34 stage renal disease) and multiple linear regression analyses for continuous variables
35
36 (age, BMI, HbA1c, insulin doses) were applied for adjustment.
37
38
39
40
41
42

43 **Results**

44
45 Data on liver enzymes from the previous 12 months were available from 270 centres.
46
47 A total of 9226 patients (29%) of the 32075 patients fulfilling the inclusion criteria
48
49 had their liver transaminases measured and reported at least once in the 12 months
50
51 observation period (Figure 1). Of the 270 centers that were reporting liver enzyme
52
53 measurements in their patients, 83 centres measured liver enzymes in at least 50% of
54
55 their patients (Table 4, supplemental material).
56
57
58
59
60

1
2
3
4
5 Total cohort.
6

7 More than half (56%) of the patients were using intensified basis bolus insulin therapy
8 using insulin pens, an additional 29% were using insulin pumps and 15% were on
9 conventional insulin therapy. In this cohort there is a high proportion of well-
10 controlled patients (40% with an HbA1c below or equaling 7.5%), but 33% have an
11 HbA1c above 9% (Table 1, third column).
12

13 Of the 9226 patients, 1824 (19.8%) had increased liver enzymes in one or more
14 measurement(s), of which 1254 (69%) had increased GGT, 870 (48%) had increased
15 ALT and 566 (31%) increased AST. In 243 (13%) patients all three liver enzymes
16 were increased.
17

18 Hypertension was present in 47% (38% on antihypertensive drugs) and dyslipidemia
19 in 63% (21% on lipid lowering drugs). A history of myocardial infarction was present
20 in 3.9%, 2.8% had suffered a stroke, 0.7% had a major limb amputation and 2.7% had
21 end stage renal disease (Table 1, third column).
22
23
24
25
26

27 Subgroup comparison between patients with increased and normal liver enzymes.
28

29 Characteristics of both groups are shown in the fourth and fifth columns of Table 1.
30 Patients with increased liver enzymes were older, had a higher BMI (both p values
31 <0.0001) and larger waist circumference (p<0.0005) than the patients with normal
32 liver enzymes, while duration of diabetes, sex distribution and proportion of people
33 with background of migration did not differ (Table 1). The group with increased liver
34 enzymes had worse glycemic control (p<0.00001), a higher proportion of patients
35 using conventional insulin therapy and a lower proportion of patients using intensified
36 or insulin pump therapy than in those with normal liver enzyme levels (all p<0.01)
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (Table 1). Lipid modifying drugs were taken by 19% in the group with normal liver
4
5 enzymes and 29% in the group with increased liver enzymes (both $p < 0.00001$).
6
7

8
9
10 After adjustment for age, sex, HbA1c, diabetes duration, migration background and
11 treatment center in linear regression models, age, BMI, HbA1c and the daily insulin
12 per body weight doses were significantly higher in the group with increased liver
13 enzymes than in the group with normal liver enzyme measurements (all adjusted
14 values are presented in Table 2; corresponding p-values < 0.0001 , Table 2). In logistic
15 regression models adjusting for age, sex, HbA1c, diabetes duration, migration
16 background and treatment center, people with increased liver enzymes were more
17 likely to have hypertension (OR: 1.48, 95% CI: 1.31-1.68) and dyslipidemia (OR 1.75,
18 95% CI: 1.54-2.00) and more likely to have had a myocardial infarction and to have
19 end stage renal disease (OR were 1.5 and 1.6, respectively, Table 2), but there was no
20 association with the prevalence of history of stroke or major amputations (Table 2).
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 Subgroup comparison between patients with increased ALT and normal ALT.

37
38 Two (or more) ALT measurements per patient were available in a subgroup of 2335
39 patients (25%). ALT was increased at least twice in 686 (29%) of these patients.
40
41 Patients with increased ALT were older, had a higher BMI and waist circumference,
42 had a higher HbA1c and a more adverse lipid profile (Table 3, supplemental
43 material). After adjustment for age, sex, HbA1c, diabetes duration, migration
44 background and treatment center in linear and logistic regression models, patients
45 with ALT were more likely to have hypertension (OR 1.58, 95% CI: 1.26-1.97) and
46 dyslipidemia (OR 1.89, 95% CI: 1.51-2.37), to be older and have a higher HbA1c and
47 BMI (Table 4, supplemental material), but there were no differences in prevalence of
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 myocardial infarction, stroke, major amputation or end stage renal disease (Table 4,
4 supplemental material).
5
6
7
8

9
10 When comparing the group of patients who were included based on the criteria above
11 (see methods section) and the availability of liver enzyme measurements (n=9226)
12 with those who fulfilled all inclusion criteria but had no liver enzyme measurements
13 available (n= 22849), the patients with available liver enzyme measurements were
14 younger, had a higher proportion of people with migration background, had a higher
15 BMI and waist circumference, higher HbA1c and daily insulin doses, lower
16 triglyceride levels and lower blood pressure (Table 5, supplemental material). The
17 prevalences of MCI, stroke, end stage renal disease were not different, but the
18 prevalence of hypertension and dyslipidemia was higher in the patients in whom liver
19 enzymes have been reported (Table 5, supplemental material).
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 The comparison between patients from centers in which liver enzymes were measured
35 in >50% of the patients (n= 5073, 55%) and those coming from centers with less
36 frequent liver enzyme measurements (n=4153, 45%) showed that patients from
37 centers with frequent liver enzyme measurements had a longer duration of diabetes, a
38 higher proportion with migration background, higher HbA1c and systolic blood
39 pressure (Table 6, supplemental material). When analyzing only data from centers
40 that measure frequently, the proportion of patients with increased liver enzymes was
41 19.4%, which is similar to the proportion reported in the total dataset (19.8%). The
42 prevalence of MCI, stroke and major amputation did not differ, but there was a higher
43 prevalence of end stage renal disease and hypertension in patients treated at centers
44 with frequent measurement of liver enzymes (Table 6, supplemental material).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

In this report we describe the prevalence of increased liver enzymes in a multicenter audit of 45519 adults with T1DM in routine clinical care. After exclusion of people with health factors known to influence hepatic function, liver enzyme measurements were available in 29% of the patients. Of these, 20% had increased liver enzymes during the course of routine clinical follow up. Elevation of liver enzymes was associated with worse glycemic control, less favorable cardiovascular risk profile and a higher prevalence of diabetes late complications (myocardial infarction and end stage renal failure).

For reports such as this to be useful to practicing clinicians, it is essential to put them in context. The prevalence of increased liver enzymes observed here compares to estimates of 10-21% in the general population [15-17] and 12% to 71% in Type 2 diabetes [18-21]. Comparing the results from our study with data from the general population is difficult because the latter will, for example, include individuals with undiagnosed liver pathologies, or individuals consuming alcohol in excess of the recommended levels. In contrast, we have excluded from our analyses people with known liver pathologies and excessive alcohol consumption. Further, people with an established diagnosis of T1DM are more likely to be taking statin therapy by virtue of the awareness of diabetes physicians of the cardiovascular risk.

A smaller observational study in approximately 900 patients with T2DM and T1DM noted that increased ALT was increased in 2-35% of T1DM and 4-51% in T2DM, depending on the cut-off used [22]. In their subgroup with patients with T1DM applying the same lower ALT threshold as we have used in our subgroup analysis, the

1
2
3 35% of patients had increased ALT was 35%, which is a higher proportion than in our
4 cohort [22].
5

6
7 Another issue that arises in the analyses of large datasets is that no clear consensus
8 exists as to where to set the cut-off thresholds for increased liver enzymes in T1DM,
9 such that the proportion of people with increased measurements depends on the
10 diagnostic threshold applied. We have used different diagnostic criteria within the
11 same DPV dataset, one applying national liver association guidelines and one using
12 lower ALT cut-off but in two measurements as suggested elsewhere [12]. Using these
13 two approaches the proportions of patients with elevated liver enzymes changes from
14 20 to 29%. However, the association with poorer glycemic control and less favorable
15 cardiovascular risk profile (dyslipidemia and hypertension) was consistent in both
16 analyses, whereas the association with diabetes complications (myocardial infarction
17 and end stage renal disease) was only significant in the analysis applying the higher
18 liver enzyme cut off thresholds of the national guidelines. This would suggest that a
19 lower ALT cut-off has the potential to identify patients with higher cardiovascular
20 risk at an earlier stage.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 In the present cross sectional analysis in people with T1DM in the DPV registry, the
42 group with increased liver enzymes had a more adverse cardiovascular risk profile
43 with a high prevalence of hypertension and dyslipidemia and worse glycemic control
44 than those with normal liver enzymes. Patients with elevated liver enzymes were also
45 more obese, suggesting a higher level of insulin resistance. Notably, the odds ratios
46 for myocardial infarction and end stage renal disease were 1.5 and 1.6, respectively,
47 when compared with the patients with normal liver enzymes and after adjustment for
48 age, HbA1c and other factors. This is in line with observations from a large,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 population-based, longitudinal study that suggested an association between elevated
4 GGT levels and all-cause and cardiovascular mortality in men [23] , and from smaller
5
6 clinic-based reports in people with T1DM in whom NAFLD was associated with an
7
8 increased incidence of chronic kidney disease [24] and with a greater prevalence of
9
10 retinopathy and nephropathy [25].
11

12
13
14 Given the audit-style nature of this report it is not possible to determine whether the
15
16 increased rates of diabetes complications in the patients with T1DM who have
17
18 increased liver enzymes are a consequence of shared conventional risk factors
19
20 (hypertension, dyslipidemia, hyperglycemia), or whether the increased liver enzymes
21
22 represent an independent risk marker in this situation. The former seems more likely.
23
24 Further, longitudinal observational studies will be needed to better understand the
25
26 relationship between increased liver enzymes and comorbidities and complications in
27
28 people with T1DM and to determine the diagnostic thresholds for increased liver
29
30 enzymes clinically relevant for people with T1DM.
31
32

33
34
35
36 Although the DPV has the potential to provide insight into routine clinical practice by
37
38 virtue of its size, our study has obvious limitations. First, the real-world character of a
39
40 clinical database is apparent in the 29% of patients in whom liver enzyme
41
42 measurements were available. This heterogeneity of clinical practice between centers
43
44 has the potential to introduce bias into our dataset. Patients who did not have their
45
46 liver enzymes reported were younger, leaner, had a better diabetes control and lower
47
48 prevalence of hypertension and dyslipidemia, which may have contributed to an
49
50 individual clinician's decision not to measure liver enzymes.
51
52

53
54 The additional comparison made between patients from centers that measure liver
55
56 enzymes in over 50% of their patients and patient from centers that measure in less
57
58
59
60

1
2
3 than 50% of patients confirmed that patients from centers with frequent liver enzyme
4
5 measurements had a longer diabetes duration, worse diabetes control, more likely to
6
7 have a migration background and had a higher prevalence of hypertension and end
8
9 stage renal disease, which altogether may have contributed to local clinical routine
10
11 standards more in favor of a risk factor assessment including liver enzymes.
12
13

14 15 16 Conclusion.

17
18 In this clinical audit in adults with T1DM, elevated liver enzymes on routine clinical
19
20 assessment were associated with a less favorable cardiovascular risk profile and
21
22 poorer glycemic control. We consider these observations worthy of reporting as they
23
24 may, if supported by future longitudinal studies from other groups, provide an
25
26 additional factor in the cardiovascular risk stratification of people with T1DM.
27
28
29
30
31

32 Acknowledgements.

33
34
35 Funding sources: BMBF Competence Net Diabetes mellitus, FKZ 01GI 1106; EFSD

36
37 Author contributions: R.W.H., M.S. and E.B. planned the analyses, E.B. and R.H.
38
39 performed the statistical analyses, M.S. wrote the manuscript, M.S., M.F., W.K., I. S.-
40
41 F., D.K., S.M., M.R., P.J., and RWH contributed data and critically revised the
42
43 manuscript.

44 Disclosure statement: the authors have got nothing to disclose.

45 We thank all DPV centres who contributed data for this analysis:

46
47 Karlsburg Klinik fuer Diabetes & Stoffwechsel, Darmstadt Innere Medizin,
48
49 Offenbach/Main Innere Medizin, Forchheim Diabeteszentrum SPP, Frankfurt
50
51 Diabeteszentrum Rhein-Main-Erwachsenendiabetologie (Buergerhospital),
52
53 Reutlingen Klinikum Steinenberg Innere, Wien 3. Med. Hietzing Innere, Bad Aibling
54
55 Internist. Praxis, Rosenheim Innere Medizin, Muenster Herz Jesu Innere, Tettnang
56
57 Innere Medizin, Frankfurt Uni-Klinik Innere, Dortmund-Hombruch Marienhospital,
58
59 Ulm Uni Innere Medizin, Frankfurt Uni-Kinderklinik, Traunstein diabetol.
60
Schwerpunktpraxis, Friedberg Innere Klinik, Kleve Innere Medizin, Muenchen
Diabetes-Zentrum Sued, Krefeld-Uerdingen St. Josef Innere, Konstanz Innere Klinik,
Herten St. Elisabeth Innere Medizin, Geislingen Klinik Helfenstein Innere, Wolgast
Innere Medizin, Freiburg Uni Innere, Lindenfels Luisenkrankenhaus Innere, L,beck

1
 2
 3 Uni-Klinik Innere Medizin, Kirchheim-Noertingen Innere, Limburg Innere Medizin,
 4 Hildesheim Kinderarztpraxis, Trostberg Innere, Wangen Oberschwabenklinik Innere
 5 Medizin, Saaldorf-Surheim Diabetespraxis, Heilbronn Innere Klinik, Innsbruck
 6 Universitaetsklinik Innere, Gelsenkirchen Kinderklinik Marienhospital, Marktredwitz
 7 Innere Medizin, Murnau am Staffelsee - diabetol. SPP, Stolberg Kinderklinik, Berlin
 8 Endokrinologikum, Deggendorf Medizinische Klinik II, Erfurt Kinderklinik, Rastatt
 9 Kreiskrankenhaus Innere, Braunfels-Wetzlar Innere, Ludwigshafen diabetol. SPP,
 10 Osterkappeln Innere, Wittenberg Innere Medizin, Wien Uni-Kinderklinik, M, nster
 11 Clemens-Hospital Innere, Linz Krankenhaus Barmherzige Schwestern Kardiologie
 12 Abt. Int. II, Wetzlar Schwerpunkt-Praxis, Plauen Vogtlandklinikum, Berlin Evang.
 13 Krankenhaus Koenigin Elisabeth, Rostock Universitaet Innere Medizin, Oldenburg
 14 Schwerpunktpraxis, Bottrop Knappschaftskrankenhaus Innere, Innsbruck
 15 Universitaetskinderklinik, Berlin Virchow-Kinderklinik, Rosenheim
 16 Schwerpunktpraxis, Koblenz Kemperhof 1. Med. Klinik, Magdeburg Uni-
 17 Kinderklinik, Bremen - Kinderklinik Nord, Herdecke Kinderklinik, Linz AKH - 2.
 18 Med, Goepfingen Kinderklinik am Eichert, Mannheim Uni-Kinderklinik, Hanau St.
 19 Vincenz - Innere, Heidelberg Uni-Kinderklinik, Wien Uni Innere Med III, Asbach
 20 Kamillus-Klinik Innere, Krefeld Innere Klinik, Augsburg Kinderklinik
 21 Zentralklinikum, Luxembourg - Centre Hospitalier, Wilhelmshaven St. Willehad
 22 Innere, Recklinghausen Dialysezentrum Innere, Schwerin Innere Medizin, Wiesbaden
 23 Kinderklinik DKD, Dortmund-St. Josefhospital Innere, Mannheim Uniklinik Innere
 24 Medizin, Sinsheim Innere, Stade Kinderklinik, Muenster paediat. Schwerpunktpraxis,
 25 Bielefeld Kinderklinik Gilead, Berlin St. Josepshospital Innere, Berlin Vivantes
 26 Hellersdorf Innere, Bocholt Kinderklinik, Graz Universitaets-Kinderklinik,
 27 Hinrichs-Klinik, Berlin Diabetikerjugendhaus, Moedling Kinderklinik, Berlin DRK-
 28 Kliniken, Hameln Kinderklinik, Herford Klinikum Kinder & Jugendliche,
 29 Kaiserslautern-Westpfalz-Klinikum Kinderklinik, Berchtesgaden CJD, Dornbirn
 30 Kinderklinik, Moers Kinderklinik, Osnabrueck Christliches Kinderhospital,
 31 Tuebingen Uni-Kinderklinik, Coesfeld Kinderklinik, Ottobeuren Kreiskrankenhaus,
 32 Ravensburg Kinderklinik St. Nikolaus, Oberhausen Kinderpraxis, Aurich
 33 Kinderklinik, Erlangen Uni Innere Medizin, Kempen Heilig Geist - Innere, Kirchen
 34 DRK Krankenhaus Kinderklinik, Koblenz Kinderklinik Kemperhof, Mainz Uni-
 35 Kinderklinik, Heidenheim Kinderklinik, Trier Kinderklinik der Borromaeerinnen,
 36 Berchtesgaden MVZ Innere Med, Berlin Klinik St. Hedwig Innere, Hamburg
 37 Endokrinologikum, Lindenfels Luisenkrankenhaus Innere 2, Muenster Uni-
 38 Kinderklinik, Gera Kinderklinik, Hamburg-Nord Kinder-MVZ, Heide Kinderklinik,
 39 Lienz Diabetesschwerpunktpraxis fuer Kinder und Jugendliche, Muenchen-
 40 Schwabing Kinderklinik, Wiesbaden Horst-Schmidt-Kinderkliniken, Berlin
 41 Schlosspark-Klinik Innere, Eutin St.-Elisabeth Innere, Garmisch-Partenkirchen
 42 Kinderklinik, Hagen Kinderklinik, Hildesheim GmbH - Innere, Krefeld Kinderklinik,
 43 Koeln Kinderklinik Amsterdamerstrasse, M, nchen-Gauting Kinderarztzentrum,
 44 Neunkirchen Marienhausklinik Kohlhof Kinderklinik, Reutlingen Kinderarztpraxis,
 45 Schwaebisch Hall Diakonie Kinderklinik, Stuttgart Bethesda Agaplesion, Weingarten
 46 Kinderarztpraxis, Wilhelmshaven Reinhard-Nieter-Kinderklinik, Aachen - Innere
 47 RWTH, Augsburg Innere, Bad Mergentheim - Gemeinschaftspraxis DM-dorf
 48 Althausen, Bonn Uni-Kinderklinik, Dortmund Medizinische Kliniken Nord, Kiel
 49 Staedtische Kinderklinik, Lappersdorf Kinderarztpraxis, Ludwigsburg Innere
 50 Medizin, Ludwigsburg Kinderklinik, Moers - St. Josefskrankenhaus Innere,
 51 Oberhausen Kinderklinik, Scheidegg Reha-Kinderklinik Maximilian, Suhl
 52 Kinderklinik, Ulm Schwerpunktpraxis Bahnhofplatz, Waldshut Kinderpraxis, Bad
 53
 54
 55
 56
 57
 58
 59
 60

1
 2
 3 Orb Spessart Klinik Reha, Darmstadt Kinderklinik Prinz. Margaret, Essen Diabetes-
 4 Schwerpunktpraxis, Frankenthal Kinderarztpraxis, Freiburg Kinder-MVZ, Gieflen
 5 Uni-Kinderklinik, Haren Kinderarztpraxis, Heidenheim Arztpraxis Allgemeinmed,
 6 Kassel Klinikum Kinder- und Jugendmedizin, Koeln Uni-Kinderklinik, M,hlacker
 7 Enzkreiskliniken Innere, Sylt Rehaklinik, Waldshut-Tiengen Kinderpraxis Biberbau,
 8 Wien SMZ Ost Donauspital, Worms Kinderklinik, Wuppertal Kinderklinik, Aachen -
 9 Uni-Kinderklinik RWTH, Bad Driburg / Bad Hermannsborn Innere, Bremen
 10 Zentralkrankenhaus Kinderklinik, Duesseldorf Uni-Kinderklinik, Freiburg Uni-
 11 Kinderklinik, Goepingen Innere Medizin, Hannover Kinderklinik auf der Bult,
 12 Iserlohn Innere Medizin, Lilienthal Diabeteszentrum, Magdeburg Staedtisches
 13 Klinikum Innere, Moenchengladbach Kinderklinik Rheydt Elisabethkrankenhaus,
 14 M,nchen Schwerpunktpraxis, Neuwied Kinderklinik Elisabeth, Offenbach/Main
 15 Kinderklinik, Oldenburg Kinderklinik, Oschersleben MEDIGREIF
 16 B^rdekrankenhaus, Pfullendorf Innere Medizin, Rastatt Gemeinschaftspraxis,
 17 Regensburg Kinderklinik St. Hedwig, Rendsburg Kinderklinik, Rotenburg/W ,mme
 18 Agaplesion Diakoniekrankenhaus Kinderabteilung, Spaichingen Innere, St. P^lten
 19 Kinderklinik, Ulm Uni-Kinderklinik, Wels Innere, Aue Helios Kinderklinik, Bad
 20 Hersfeld Kinderklinik, Bad Koesen Kinder-Rehaklinik, Bad Lauterberg
 21 Diabeteszentrum Innere, Bad Salzungen Kinderklinik, Bayreuth Innere Medizin,
 22 Berlin Parkklinik Weissensee, Bochum Universitaetskinderklinik St. Josef,
 23 Bremerhaven Kinderklinik, Coesfeld/Duelmen Innere Med., Datteln Vestische
 24 Kinderklinik, Duisburg-St.Johannes Helios, Eisleben Lutherstadt Helios-Klinik,
 25 Erlangen Uni-Kinderklinik, Feldkirch Kinderklinik, Hamburg Kinderklinik
 26 Wilhelmstift, Hamm Kinderklinik, Hanau Kinderklinik, Hannover Kinderklinik
 27 MHH, Heringsdorf Inselklinik, Hof Kinderklinik, Itzehoe Kinderklinik,
 28 Kaiserslautern Kinderarztpraxis, Kempten Oberallgaeu Kinderklinik, Leverkusen
 29 Kinderklinik, Linz Landes-Kinderklinik, L,beck Uni-Kinderklinik, Marburg - UKGM
 30 Endokrinologie & Diabetes, Minden Kinderklinik, Mutterstadt Kinderarztpraxis,
 31 Muenchen Kinderarztpraxis diabet. SPP, M,nchen von Haunersche Kinderklinik,
 32 Nauen Havellandklinik, N,rnberg Cnopfsche Kinderklinik, Oberhausen St.Clemens
 33 Hospitale Sterkrade, Oy-Mittelberg Hochgebirgsklinik Kinder-Reha, Pforzheim
 34 Kinderklinik, Prenzlau Krankenhaus Innere, Rheine Mathiasspital Kinderklinik,
 35 Saarbruecken Kinderklinik Winterberg, Salzburg Kinderklinik, Schweinfurt
 36 Kinderklinik, Siegen Kinderklinik, Ulm Endokrinologikum, Weiden Kinderklinik,
 37 Weisswasser Kreiskrankenhaus, Wernberg-Koebnitz SPP, Wien Wilhelminenspital 5.
 38 Med. Abteilung,
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

References

- [1] Standards of medical care in diabetes--2014. *Diabetes Care*. 2014; **37**
Suppl 1: S14-80
 [2] El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic
 liver disease and hepatocellular carcinoma. *Gastroenterology*. 2004; **126**: 460-
 468
 [3] Suh S, Kim KW. Diabetes and cancer: is diabetes causally related to
 cancer? *Diabetes & metabolism journal*. 2011; **35**: 193-198

- 1
2
3 [4] Williamson DF, Madans J, Anda RF, Kleinman JC, Giovino GA, Byers T.
4 Smoking cessation and severity of weight gain in a national cohort. *N Engl J Med.*
5 1991; **324**: 739-745
- 6 [5] Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR.
7 Prevalence and associated factors of non-alcoholic fatty liver disease in patients
8 with type-2 diabetes mellitus. *Liver international : official journal of the*
9 *International Association for the Study of the Liver.* 2009; **29**: 113-119
- 10 [6] Targher G, Bertolini L, Rodella S, *et al.* Nonalcoholic fatty liver disease is
11 independently associated with an increased incidence of cardiovascular events
12 in type 2 diabetic patients. *Diabetes Care.* 2007; **30**: 2119-2121
- 13 [7] Merger SR, Kerner W, Stadler M, *et al.* Prevalence and comorbidities of
14 double diabetes. *Diabetes Res Clin Pract.* 2016; **119**: 48-56
- 15 [8] Schwab KO, Doerfer J, Hecker W, *et al.* Spectrum and prevalence of
16 atherogenic risk factors in 27,358 children, adolescents, and young adults with
17 type 1 diabetes: cross-sectional data from the German diabetes documentation
18 and quality management system (DPV). *Diabetes Care.* 2006; **29**: 218-225
- 19 [9] Vajro P, Paoletta G, Maggiore G, Giordano G. Pediatric celiac disease,
20 cryptogenic hypertransaminasemia, and autoimmune hepatitis. *J Pediatr*
21 *Gastroenterol Nutr.* 2013; **56**: 663-670
- 22 [10] Rosenbauer J, Dost A, Karges B, *et al.* Improved metabolic control in
23 children and adolescents with type 1 diabetes: a trend analysis using prospective
24 multicenter data from Germany and Austria. *Diabetes Care.* 2012; **35**: 80-86
- 25 [11] The effect of intensive treatment of diabetes on the development and
26 progression of long-term complications in insulin-dependent diabetes mellitus.
27 The Diabetes Control and Complications Trial Research Group. *N Engl J Med.*
28 1993; **329**: 977-986
- 29 [12] Prati D, Taioli E, Zanella A, *et al.* Updated definitions of healthy ranges for
30 serum alanine aminotransferase levels. *Ann Intern Med.* 2002; **137**: 1-10
- 31 [13] Whitworth JA. 2003 World Health Organization (WHO)/International
32 Society of Hypertension (ISH) statement on management of hypertension. *J*
33 *Hypertens.* 2003; **21**: 1983-1992
- 34 [14] Silveiro SP, Araujo GN, Ferreira MN, Souza FD, Yamaguchi HM, Camargo
35 EG. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
36 pronouncedly underestimates glomerular filtration rate in type 2 diabetes.
37 *Diabetes Care.* 2011; **34**: 2353-2355
- 38 [15] Radcke S, Dillon JF, Murray AL. A systematic review of the prevalence of
39 mildly abnormal liver function tests and associated health outcomes. *European*
40 *journal of gastroenterology & hepatology.* 2015; **27**: 1-7
- 41 [16] Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G. The clinical
42 significance of slightly to moderately increased liver transaminase values in
43 asymptomatic patients. *Scandinavian journal of gastroenterology.* 1999; **34**: 85-
44 91
- 45 [17] Bonnet F, Ducluzeau PH, Gastaldelli A, *et al.* Liver enzymes are associated
46 with hepatic insulin resistance, insulin secretion, and glucagon concentration in
47 healthy men and women. *Diabetes.* 2011; **60**: 1660-1667
- 48 [18] Mor A, Svensson E, Rungby J, *et al.* Modifiable clinical and lifestyle factors
49 are associated with elevated alanine aminotransferase levels in newly diagnosed
50 type 2 diabetes patients: results from the nationwide DD2 study.
51 *Diabetes/metabolism research and reviews.* 2014; **30**: 707-715
- 52
53
54
55
56
57
58
59
60

- 1
2
3 [19] Giandalia A, Romeo EL, Ruffo MC, *et al.* Clinical correlates of persistently
4 elevated liver enzymes in type 2 diabetic outpatients. Primary care diabetes.
5 2016:
6
7 [20] Bora K, Borah M, Chutia H, Nath CK, Das D, Ruram AA. Presence of
8 Concurrent Derangements of Liver Function Tests in Type 2 Diabetes and Their
9 Relationship with Glycemic Status: A Retrospective Observational Study from
10 Meghalaya. Journal of laboratory physicians. 2016; **8**: 30-35
11 [21] West J, Brousil J, Gazis A, *et al.* Elevated serum alanine transaminase in
12 patients with type 1 or type 2 diabetes mellitus. QJM. 2006; **99**: 871-876
13 [22] Leeds JS, Forman EM, Morley S, Scott AR, Tesfaye S, Sanders DS. Abnormal
14 liver function tests in patients with Type 1 diabetes mellitus: prevalence, clinical
15 correlations and underlying pathologies. Diabet Med. 2009; **26**: 1235-1241
16 [23] Haring R, Wallaschofski H, Nauck M, Dorr M, Baumeister SE, Volzke H.
17 Ultrasonographic hepatic steatosis increases prediction of mortality risk from
18 elevated serum gamma-glutamyl transpeptidase levels. Hepatology. 2009; **50**:
19 1403-1411
20 [24] Targher G, Mantovani A, Pichiri I, *et al.* Nonalcoholic fatty liver disease is
21 independently associated with an increased incidence of chronic kidney disease
22 in patients with type 1 diabetes. Diabetes Care. 2014; **37**: 1729-1736
23 [25] Vendhan R, Amutha A, Anjana RM, Unnikrishnan R, Mohan V. Clinical
24 Profile of Non Alcoholic Fatty Liver Disease Among Young Patients with Type 1
25 Diabetes Mellitus Seen at a Diabetes Speciality Centre in India. Endocrine
26 practice : official journal of the American College of Endocrinology and the
27 American Association of Clinical Endocrinologists. 2014: 1-24
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legends to Figures

Figure 1.

Flow chart of patient inclusion and exclusion for the final analysis.

DPV, Diabetes Prospective Documentation; ALT, alanine-aminotransferase; AST, aspartate-aminotransferase; GGT, gamma-glutamyl transferase.

Legends to Tables.

Table 1.

Anthropometric, clinical and laboratory characteristics of patients with T1DM with increased ALT, AST and/or GGT compared with patients with normal ALT, AST and GGT and prevalence of diabetes late complications and comorbidities (un-adjusted percentages).

Data are presented as median (Q1, Q3). P-values for subgroup comparisons for continuous variables are derived from non-parametric testing applying Wilcoxon tests and from χ^2 tests for binominally distributed variables. P values adjusted for multiple comparisons using the Holm method.


T1DM, type 1 diabetes mellitus; BMI, body mass index; HbA1c, glycated Hemoglobin A1c; BP, blood pressure; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; GGT, gamma-glutamyl-transferase; LDL-cholesterol, low-density lipoprotein cholesterol; HDL-cholesterol, high density lipoprotein cholesterol;

Table 2.

Comparison of prevalence of comorbidities and complications by means of logistic regression models (with adjustment for age, sex, diabetes duration, migration background, HbA1c and treatment center) and comparison of age, BMI, insulin doses and HbA1c using linear regression models (*) (with adjustment for age, sex, diabetes duration, migration background, HbA1c and treatment center) between patients with increased and with normal liver enzymes.

Data are presented as means \pm standard error of the means and adjusted p-values. OR, odds ratios with 95% CI, confidence intervals. BMI, body mass index; HbA1c, glycated Hemoglobin A1c;

Figure 1.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1.

| | Datasets | Total cohort | Increased Liver enzymes | Normal Liver enzymes | p-value |
|---|----------|--------------------------------|--------------------------------|--------------------------------|-----------------|
| N | 9226 | | 1824 | 7402 | |
| Female (%) | 9226 | 46 | 49 | 45 | 0.2 |
| Age (yrs) | 9226 | 42.2 (27.1, 56.7) | 49.4 (36.0, 61.9) | 40.0 (25.7, 54.9) | <0.000001 |
| Migration background (%) | 9226 | 4.0 | 3.6 | 4.2 | 1.0 |
| Duration of T1DM (yrs) | 9226 | 15.0 (7.1, 25.9) | 15.6 (6.5, 28.8) | 14.8 (7.3, 25.4) | 1.0 |
| BMI (kg/m²) | 9155 | 25.0 (22.5, 28.2) | 25.7 (22.8, 29.9) | 24.8 (22.5, 27.9) | <0.000001 |
| BMI>= 30kg/m² (%) | 9155 | 17 | 25 | 15 | |
| Waist circumference (cm) | 2198 | 92 (84, 101) | 94 (87, 107) | 91 (84, 100) | 0.0005 |
| HbA1c (%) | 9119 | 7.9 (7.0, 9.1) | 8.1 (7.1, 9.8) | 7.8 (6.9, 9.0) | <0.000001 |
| HbA1c (mmol/mol) | | 62 (53, 76) | 65 (54, 83) | 62 (52, 75) | |
| HbA1c <=7.5% (%) | | 40 | 34 | 42 | |
| HbA1c > 9.0% (%) | | 33 | 32 | 24 | |
| Insulin dosis (IU/kg/day) | 9226 | 0.62 (0.46, 0.82) | 0.62 (0.46, 0.83) | 0.62 (0.46, 0.82) | 1.0 |
| Diabetes therapy | 9226 | | | | |
| Conventional insulin therapy | | 15% | 19% | 15% | 0.0006 |
| Intensified insulin therapy | | 56% | 60% | 55% | 0.002 |
| Insulin pump | | 29% | 21% | 30% | <0.00001 |
| BP systolic/diastolic (mmHg) | 9008 | 126 (119, 138) /76 (70, 80) | 130 (120, 140) /76 (70, 80) | 125 (119, 137) /76 (70, 80) | <0.0001/ 1.0 |
| Total cholesterol (mg/dl) | 8409 | 190 (164, 218) | 197 (165, 228) | 189 (163, 216) | <0.00001 |
| LDL-cholesterol (mg/dl) | 7930 | 107 (85, 132) | 110 (84, 140) | 106 (85, 130) | 0.02 |
| HDL-cholesterol (mg/dl) | 8034 | 58 (46, 72) | 54 (41, 69) | 59 (48, 73) | <0.00001 |
| Triglycerides (mg/dl) | 8252 | 100 (71, 149) | 124 (85, 194) | 95 (69, 140) | <0.00001 |
| ALT (U/l) | 8681 | 20 (15, 29) | 38 (25, 58) | 19 (14, 24) | <0.00001 |
| AST (U/l) | 6717 | 21 (17, 28) | 34 (24, 49) | 20 (16, 24) | <0.00001 |
| GGT (U/l) | 8432 | 20 (14, 34) | 64 (39, 105) | 18 (13, 25) | <0.00001 |
| No alcohol consumption | | 81% | 85% | 81% | 0.02 |
| Alcohol consumption g/day (in those consuming alcohol) | 925 | 5 (3, 10) | 6 (3, 11) | 5 (2,10) | 0.2 |
| Myocardial infarction (%) | 9226 | 3.9 | 6.4 | 3.2 | <0.00001 |
| Stroke (%) | 9226 | 2.8 | 4.1 | 2.5 | 0.004 |
| Major amputation (%) | 9226 | 0.7 | 1.4 | 0.5 | 0.001 |
| End stage renal disease (%) | 9015 | 2.7 | 4.1 | 2.3 | 0.0004 |
| Hypertension (%) | 9082 | 47 | 59 | 44 | <0.00001 |
| Dyslipidemia (%) | 8671 | 63 | 78 | 60 | <0.00001 |

Table 2.

| | Increased Liver enzymes | Normal Liver enzymes | Adj. p value | Odds Ratio (95% CI) |
|------------------------------------|-------------------------------|-------------------------|-----------------|---------------------|
| Hypertension (%) | 57.3±2.1 | 47.5±1.7 | <0.0001 | 1.48 (1.31-1.68) |
| Dyslipidaemia (%) | 73.7±1.3 | 61.5±1.0 | <0.0001 | 1.75 (1.54-2.00) |
| Myocardial infarction (%) | 2.7± 0.4 | 1.8±0.2 | 0.002 | 1.49 (1.17-1.91) |
| Stroke (%) | 1.78±0.3 | 1.5±0.2 | 0.28 | 1.17 (0.88-1.60) |
| Major amputation (%) | 0.66±0.16 | 0.33±0.07 | 0.23 | 1.99 (0.07-57) |
| End stage renal disease (%) | 3.0±0.5 | 1.9±0.2 | 0.004 | 1.59 (1.17-2.17) |
| Age * | 39.5±0.8 | 35.5±0.7 | <0.0001 | |
| BMI * | 26.4±0.1 | 25.2±0.1 | <0.0001 | |
| Insulin dosis (IU/kg/day) * | 0.74±0.01 | 0.71±0.01 | <0.0001 | |
| HbA1c (%)* | 8.2±0.1 | 7.9±0.1 | <0.0001 | |

Table 3.**Subgroup analysis of patients in whom ALT was increased above 30 U/l in males and 19 U/l in females on at least two occasions.**

Anthropometric, clinical and laboratory characteristics of the patients with T1DM with increased and normal ALT.

Data are presented as median (Q1, Q3). P-values for subgroup comparisons for continuous variables are derived from non-parametric testing applying Wilcoxon tests and from χ^2 tests for binominally distributed variables. P values adjusted for multiple comparisons using the Holm method.

T1DM, type 1 diabetes mellitus; BMI, body mass index; HbA1c, glycated Hemoglobin A1c; BP, blood pressure; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; GGT, gamma-glutamyl-transferase; LDL-cholesterol, low-density lipoprotein cholesterol; HDL-cholesterol, high density lipoprotein cholesterol;

| Patients with ≥ 2 ALT measurements available | Increased ALT (\geqtwice) | Normal ALT | p-value | Total subgroup |
|---|---|--------------------------------|----------------|------------------------------|
| N | 686 | 1649 | <0.00001 | 2335 |
| Female (%) | 56 | 42 | | 46 |
| Age (yrs) | 46.1 (31.6, 57.9) | 41.0 (26.5, 55.8) | <0.002 | 42.8 (28.2-56.5) |
| Migration background | 3.0 | 1.5 | 0.78 | 2.5 |
| Duration of T1DM (yrs) | 15.9 (6.5, 27.7) | 15.9 (7.8, 26.4) | 1.0 | 15.9 (7.5-26.7) |
| BMI (kg/m²) | 26.4 (23.5, 29.9) | 25.0 (22.6, 28.0) | <0.00001 | 25.3 (22.9-28.6) |
| Waist circumference (cm) | 94 (87, 101) | 92 (85, 99) | 0.15 | 92 (86-99) |
| Insulin dosis (IU/kg/ day) | 0.62 (0.47-0.81) | 0.62 (0.48-0.81) | 1.0 | 0.62 (0.48-0.81) |
| HbA1c (%) | 8.2 (7.3, 9.8) | 7.8 (7.0, 8.9) | <0.000001 | 7.9 (7.1-9.0) |
| HbA1c (mmol/mol) | 66 (56, 83) | 62 (53, 73) | | 63 (54-75) |
| BP systolic/diastolic (mmHg) | 125 (120, 137) /78 (70, 80) | 125 (118, 134) /75 (70, 80) | 0.9/0.9 | 125 (119-135)/ 76 (70-80) |
| Total cholesterol (mg/dl) | 200 (172, 228) | 185 (162, 212) | <0.000001 | 189 (164-217) |
| LDL-cholesterol (mg/dl) | 112 (87, 136) | 102 (82, 125) | <0.000001 | 104 (83-128) |
| HDL-cholesterol (mg/dl) | 57 (46, 74) | 59 (48, 72) | 1.0 | 59 (47-73) |
| Triglycerides (mg/dl) | 108 (74, 162) | 95 (70, 138) | <0.000001 | 98 (70-147) |
| ALT U/l | 33 (25, 45) | 17 (14, 22) | <0.000001 | 20 (16-28) |
| AST U/l | 29 (23, 39) | 20 (16, 24) | <0.000001 | 21 (17-28) |
| GGT U/l | 27 (16, 46) | 17 (13, 26) | <0.000001 | 19 (13-32) |
| Myocardial infarction (%) | 3.0 | 4.5 | 1.0 | 4.1 |
| Stroke (%) | 2.6 | 2.5 | 1.0 | 2.5 |
| Major amputation (%) | 1.0 | 1.0 | 1.0 | 1.0 |
| End stage renal disease (%) | 3.0 | 3.6 | 1.0 | 3.4 |
| Hypertension (%) | 57 | 47 | 0.0008 | 50 |
| Dyslipidemia (%) | 76 | 61 | <0.000001 | 65 |

Table 4.**Subgroup analysis of patients in whom ALT was increased above 30 U/l in males and 19 U/l in females on at least two occasions.**

Comparison of prevalence of comorbidities and complications by means logistic regression models (with adjustment for age, sex, diabetes duration, migration background, HbA1c and treatment center) and of age, BMI, insulin doses and HbA1c using linear regression models (*) (with adjustment for age, sex, diabetes duration, migration background, HbA1c and treatment center) between patients with increased and with normal ALT.

Data are presented as means \pm standard error of the means and adjusted p-values.

BMI, body mass index; glycated Hemoglobin A1c;

| Patients with ≥ 2 ALT measurements available | Increased ALT (\geq twice) | Normal ALT | Adj. p value | Odds Ratio (95% CI) |
|---|--|-------------------|---------------------|----------------------------|
| Hypertension (%) | 60.6 \pm 3.0 | 49.4 \pm 2.6 | <0.0001 | 1.58 (1.26-1.97) |
| Dyslipidaemia (%) | 77.9 \pm 2.0 | 65.0 \pm 1.9 | <0.0001 | 1.89 (1.51-2.37) |
| Myocardial infarction (%) | 2.4 \pm 0.6 | 2.9 \pm 0.6 | 0.37 | 0.80 (0.50-1.29) |
| Stroke (%) | 1.1 \pm 1.2 | 0.8 \pm 9.8 | 0.43 | 1.27 (0.70-2.33) |
| Major amputation (%) | 0.74 \pm 0.3 | 0.69 \pm 0.2 | 0.89 | 1.08 (0.003-418) |
| End stage renal disease (%) | 2.2 \pm 0.5 | 2.7 \pm 0.4 | 0.58 | 0.81 (0.025-25.9) |
| Age * | 40.6 \pm 1.3 | 38.1 \pm 1.2 | <0.0001 | |
| BMI * | 26.5 \pm 0.2 | 25.1 \pm 0.2 | <0.0001 | |
| Insulin dosis (IU/kg/day) * | 0.71 \pm 0.02 | 0.70 \pm 0.02 | 0.59 | |
| HbA1c (%)* | 8.4 \pm 0.1 | 7.8 \pm 0.1 | <0.0001 | |

Table 5.

Anthropometric, clinical and laboratory characteristics of the total cohort of patients with T1DM in whom liver enzymes were measured compared with patients in whom no liver enzyme measurements were available.

T1DM, type 1 diabetes mellitus; BMI, body mass index; HbA1c, glycated Hemoglobin A1c; BP, blood pressure; LDL-cholesterol, low-density lipoprotein cholesterol; HDL-cholesterol, high density lipoprotein cholesterol;

Data are presented as median (Q1, Q3). P-values for subgroup comparisons for continuous variables are derived from non-parametric testing applying Wilcoxon tests and from χ^2 tests for binominally distributed variables. P values adjusted for multiple comparisons using the Holm method.

| Comparison patients with liver enzyme measurements available/not available | Liver enzymes measured | Liver enzymes not measured | p-value |
|--|--------------------------------|--------------------------------|------------------|
| N | 9226 | 22849 | |
| Female (%) | 46 | 47 | 1.0 |
| Age (yrs) | 42.2 (27.0, 56.1) | 43.6 (28.4, 58.0) | <0.0001 |
| Migration background | 4.0% | 1.9% | <0.0001 |
| Duration of T1DM (yrs) | 15.0 (7.1, 25.9) | 15.0 (6.7, 26.7) | 1.0 |
| BMI (kg/m²) | 25.0 (22.5, 28.2) | 24.8 (22.3, 28.0) | <0.002 |
| Waist circumference (cm) | 92 (84, 101) | 89 (81, 98) | <0.00001 |
| HbA1c (%) | 7.9 (7.0, 9.1) | 7.7 (6.8, 9.1) | <0.00001 |
| HbA1c (mmol/mol) | 62 (53, 76) | 61 (51, 76) | |
| Insulin dosis (IU/kg/day) | 0.62 (0.46, 0.82) | 0.61 (0.45, 0.81) | 0.004 |
| BP systolic/diastolic (mmHg) | 126 (119, 138) /76 (70, 80) | 128 (120, 140) /78 (70, 80) | 0.0002/ 0.001 |
| Total cholesterol (mg/dl) | 190 (164, 218) | 190 (163, 220) | 1.0 |
| LDL-cholesterol (mg/dl) | 107 (85, 132) | 106 (82, 131) | 0.1 |
| HDL-cholesterol (mg/dl) | 58 (46, 72) | 57 (45, 72) | 0.1 |
| Triglycerides (mg/dl) | 100 (71, 149) | 106 (74, 159) | <0.0001 |
| No alcohol consumption | 81% | 82% | 1.0 |
| Alcohol consumption g/day (in those consuming alcohol) | 5 (3, 10) | 5 (3,10) | 1.0 |
| Myocardial infarction (%) | 3.9 | 3.7 | 1.0 |
| Stroke (%) | 2.8 | 2.7 | 1.0 |
| Major amputation (%) | 0.7 | 0.7 | 1.0 |
| End stage renal disease (%) | 2.7 | 3.2 | 0.1 |
| Hypertension (%) | 47 | 41 | <0.000001 |
| Dyslipidemia (%) | 63 | 66 | <0.005 |

Table 6.

Anthropometric, clinical and laboratory characteristics of the patients with T1DM in centers where liver enzymes were measured in at least 50% of the patients (83 of the 270 centres) compared with patients from centers that measure less frequently.

T1DM, type 1 diabetes mellitus; BMI, body mass index; HbA1c, glycated Hemoglobin A1c; BP, blood pressure; LDL-cholesterol, low-density lipoprotein cholesterol; HDL-cholesterol, high density lipoprotein cholesterol;

Data are presented as median (Q1, Q3). P-values for subgroup comparisons for continuous variables are derived from non-parametric testing applying Wilcoxon tests and from χ^2 tests for binominally distributed variables. P values adjusted for multiple comparisons using the Holm method.

| | Patients from centres with $\geq 50\%$ patients liver enzymes measured | Patients from centres with $< 50\%$ patients liver enzymes measured | p-value |
|-------------------------------------|---|--|--------------|
| N | 5073 | 4153 | |
| Female (%) | 47 | 45 | 0.9 |
| Age (yrs) | 41.8 (27.1, 56.1) | 42.6 (27.1, 57.4) | 1.0 |
| Migration background | 5.6% | 2.0% | < 0.000001 |
| Duration of T1DM (yrs) | 16.0 (7.6, 28.0) | 13.9 (6.5, 24.0) | < 0.000001 |
| BMI (kg/m²) | 25.0 (22.5, 28.3) | 24.9 (22.4, 28.2) | 1.0 |
| Waist circumference (cm) | 92 (85, 101) | 90 (82, 99) | 0.06 |
| HbA1c (%) | 8.0 (7.1, 9.2) | 7.6 (6.8, 9.0) | < 0.000001 |
| HbA1c (mmol/mol) | 63 (54, 78) | 60 (51, 74) | < 0.000001 |
| BP systolic/diastolic (mmHg) | 125 (118, 137) /75 (70, 80) | 128 (120, 139) /76 (70, 80) | 0.006/0.1 |
| Total cholesterol (mg/dl) | 189 (162, 217) | 191 (165, 219) | 0.2 |
| LDL-cholesterol (mg/dl) | 106 (83, 132) | 108 (87, 132) | 0.1 |
| HDL-cholesterol (mg/dl) | 58 (47, 72) | 58 (46, 72) | 1.0 |
| Triglycerides (mg/dl) | 99 (71, 149) | 101 (72, 149) | 1.0 |
| Heart attack | 3.6% | 4.2% | 1.0 |
| Stroke | 2.7% | 3.0% | 1.0 |
| Major amputation | 0.8% | 0.7% | 1.0 |
| End stage renal disease | 3.3% | 1.9% | 0.0004 |
| Hypertension | 49% | 44% | 0.0003 |
| Dyslipidemia | 63% | 63% | 1.0 |